9 results
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
The aim of the present study is to assess the contraceptive potential of the association of UPA 30 mg single dose and desogestrel 75 micrograms for 20 days. The study will also assess the potential possible interaction, (in terms of ovarian activity…
There are four main objectives in this research project, belonging to two different parts of the study. Part 1 comprises objectives 1 and 2:1. Determine the electrode discrimination abilities of prelingually deafened adult CI users in order to…
The effect of pulse rate on temporal resolution and speech intelligibility in cochlear implant users
To determine the (in)direct effect of CI pulse rate on speech intelligibility by means of (1) a standard test for temporal resolution: amplitude modulation detection (AMD) at two different modulation frequencies, (2) speech intelligibility tests (…
Primary objectives• To identify the percentage of patients in which a drug resistant clone can be detected with ctDNA before the emergence of radiological progression.• To determine the success rate of crizotinib and osimertinib combination…
The primary objective of this randomized controlled trial is to investigate the efficacy of dashboard driven dosing of infliximab compared to standard dosing during the induction phase in patients with acute severe ulcerative colitis, as evaluated…
Primary• To determine the RP2D of crizotinib in combination with temsirolimus • To determine the safety and preliminary activity of single-agent crizotinib in ALK, MET or ROS1 positive tumors Secondary• To study the preliminary activity of…
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
This study will evaluate the efficacy and safety of entrectinib compared with crizotinib in patients who have NSCLC harboring ROS1 gene rearrangements with and without CNS metastases. Specific objectives and corresponding endpoints for the study are…